{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"31.5","upperLimit":"59.1","value":"45.0"},{"groupId":"OG001","lowerLimit":"13.6","upperLimit":"65.0","value":"36.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"11"}],"units":"Participants"}],"description":"Percent of patients who are alive and without documented progression after at least 2-years of follow-up. All patients who receive study treatment are assessed including those who have died or lost to follow-up prior to 2-years. Progression was defined as an increase in SPEP \\[25% and an absolute increase of 0.5g/d\\] or UPEP \\[25% and an absolute increase of 200mg/24hours\\] on 2 successive evaluations as determined by the IMWG response criteria or documented progression by the FreeLite progressive disease criteria in the absence of serum or urine involvement.","dispersionType":"90% Confidence Interval","groups":[{"description":"•Drug: Elotuzumab 10 mg/kg IV; Days 1, 8,15, 22 Cycles 1-2 10 mg/kg IV; Days 1 \\& 15 Cycles 3-8\n\nOther Name: HuLuc63\n\n•Drug: Lenalidomide 25 mg Oral; Days 1-21 days Cycles 1-24\n\nOther Name: REVLIMID\n\n•Drug: Dexamethasone 40 mg Oral; Days 1, 8, 15, 22 Cycles 1-2 40 mg Oral; Days 1, 8, 15 Cycles 3-8\n\nOther Name: Decadron\n\nElotuzumab: 10 mg/kg IV; Days 1, 8,15, 22 Cycles 1-2 10 mg/kg IV; Days 1 \\& 15 Cycles 3-8\n\nLenalidomide: 25 mg Oral; Days 1-21 days Cycles 1-24\n\nDexamethasone: 40 mg Oral; Days 1, 8, 15, 22 Cycles 1-2 40 mg Oral; Days 1, 8, 15 Cycles 3-8","id":"OG000","title":"Elo / Len / Dex"},{"description":"•Drug: Elotuzumab 10 mg/kg IV; Days 1, 8,15, 22 Cycles 1-2 10 mg/kg IV; Days 1 \\& 15 Cycles 3-8\n\nOther Name: HuLuc63\n\n•Drug: Lenalidomide 25 mg Oral; Days 1-21 days Cycles 1-24\n\nOther Name: REVLIMID\n\nElotuzumab: 10 mg/kg IV; Days 1, 8,15, 22 Cycles 1-2 10 mg/kg IV; Days 1 \\& 15 Cycles 3-8\n\nLenalidomide: 25 mg Oral; Days 1-21 days Cycles 1-24","id":"OG001","title":"Elo / Len"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"2 Years","title":"Percent of Patients Who Are Progression Free at 2 Years","type":"PRIMARY","unitOfMeasure":"percentage of participants"}